Celltrion’s Regdanvimab (CT-P59) Receives the ANVISA’s EUA for the Treatment of COVID-19 in Brazil

 Celltrion’s Regdanvimab (CT-P59) Receives the ANVISA’s EUA for the Treatment of COVID-19 in Brazil

Celltrion’s Herzuma (biosimilar, trastuzumab) Overtook the Original Treatments for Cancer

Shots:

  • The EUA is based on P-III study evaluating regdanvimab vs PBO in adults with COVID-19 who do not require supplemental oxygen & are at high risk of progression to severe COVID-19
  • The results demonstrated a 72% reduction in risk of COVID-19 related hospitalization or death in high-risk patients & 70% for all patients, shortened time to clinical recovery (4.7 vs 4.9 days). The therapy also showed a safety, tolerability, antiviral effect & efficacy profile
  • Additionally, in vitro & in vivo studies demonstrated the potency of regdanvimab against multiple variants of concern including Alpha, Beta, Gamma & Delta variants. The therapy also showed strong neutralizing capability against Lambda variant

Click here to­ read full press release/ article | Ref: Celltrion | Image: Pulse News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post